SUNNYVALE, Calif., May 30 /PRNewswire/ -- Scios Inc. (Nasdaq: SCIO)
announced today that it is commencing a public offering of 5,000,000 shares of
its common stock. The managing underwriters for the offering will be
JPMorgan, Lehman Brothers and SG Cowen Securities Corporation. The
underwriters have the option to purchase up to an additional 750,000 shares to
cover over-allotments, if any.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Scios is a biopharmaceutical company developing novel treatments for
cardiovascular and inflammatory disease. The Company's disease-based
technology platform integrates expertise in protein biology with computational
and medicinal chemistry to identify novel targets and rationally design small
molecule compounds for large markets with unmet medical needs.
The offering will be made by means of a prospectus supplement and
accompanying prospectus. Copies of the prospectus supplement and the
accompanying prospectus relating to the offering may be obtained by contacting
JPMorgan, 1 Bush Street, San Francisco, CA 94104, 415-439-3000;
Lehman Brothers, 3 World Financial Center, New York, NY 10285, 212-526-7000;
or SG Cowen Securities Corporation, 1 Financial Square, 27th Floor,
New York, NY 10005, 212-495-6000.
SOURCE Scios Inc.
 back to top
Related links:
http://www.sciosinc.com
CONTACT:
Wendy Carhart of Scios Inc., 408-616-8325
|
